The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Advances and perspectives of PARP inhibitors
Open accessAbstract
DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive genome instability and catastrophic DNA damage. Continuous DNA replication in cancer cells leads to higher demand of DNA repair components. Due to the oncogenic loss of some DNA repair effectors (e.g. BRCA) and incomplete DNA repair repertoire, some cancer cells are addicted to certain DNA repair pathways such as Poly (ADP-ribose) polymerase (PARP)-related single-strand break repair pathway. The interaction between BRCA and PARP is a form of synthetic lethal effect which means the simultaneously functional loss of two genes lead to cell death, while defect in any single gene has a slight effect on cell viability. Based on synthetic lethal theory, Poly (ADP-ribose) polymerase inhibitor (PARPi) was developed aiming to selectively target cancer cells harboring BRCA1/2 mutations. Recently, a growing body of evidence indicated that a broader population of patients could benefit from PARPi therapy far beyond those with germline BRCA1/2 mutated tumors. Numerous biomarkers including homologous recombination deficiency and high level of replication pressure also herald high sensitivity to PARPi treatment. Besides, a series of studies indicated that PARPi-involved combination therapy such as PARPi with additional chemotherapy therapy, immune checkpoint inhibitor, as well as targeted agent had a great advantage in overcoming PARPi resistance and enhancing PARPi efficacy. In this review, we summarized the advances of PARPi in clinical application. Besides, we highlighted multiple promising PARPi-based combination strategies in preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 PARP and PARPis. a The structure schematic of PARP molecule. There are six main domains of PARP1 which include three zinc finger-related domains (DNA binding domains), one BRCA1 C-terminus domain (auto-modification domain), one tryptophan-/glycine-/arginine-rich domain (WGR domain), and one catalytic domain. The catalytic domain of PARP1 consists of two subdomains: one helical domain (HD) and one ADP-ribosyltransferase catalytic domain (ART). b Three-dimensional structure of PARP1 molecule. The above structures were presented by PyMOL Molecular Graphics System (PDB ID: 5XST [104]). c The chemistry structural formula of PARPis. d The function of PARP and synthetic lethal interaction between PARP and HR. Once DNA SSB emerges, PARP1 could recognizes and interacts with SSB by its zinc finger-related domains. After PARP1 binding to damaged DNA chains, the auto-inhibitory function of HD is abrogated and the catalytic function of ART is activated. This catalytic activity leads to the generation of PAR chains on a series of target proteins which promotes the recruitment of DNA repair effectors and chromatin remodeling. Then the auto-PARylation on PARP1 protein causes the dissociation of PARP1 from DNA chains and restores the auto-inhibitory status of PARP1. For HR deficient tumor cells, active SSB repair pathways is the vital prerequisites for cell survival. After PARPi treatment, NHEJ is used to repair PARPi-introduced DSB. However, NHEJ is a rapid as well as error-prone repair pathway by direct ligation. Due to the low-fidelity, NHEJ often produces plenty of chromosomal rearrangements and these unsustainable DNA damages are harmful to cell viability](/paper-figures/b8cba8b0fd6c416cb14979296998b864/advances-and-perspectives-of-parp-inhibitors-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the core of SSB repair, PARP is the ideal target for drug development [222].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [222]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X. L., Fernandez‐Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,362
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,975
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,734
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,022
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 898
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.017 · Cited by 877
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Self-citationLoibl, S., O'Shaughnessy, J., Untch, M., Sikov, W., Rugo, H., McKee, M., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 676
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Self-citationThe PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M. D., Omlin, A. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 564
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A. M., Yau, C. S. F., Veer, L. V. ‘., Buxton, M., Hogarth, M. A., Hylton, N. M., Paoloni, M. C., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 556
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J. S., Giri, U. P., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 553
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 546
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 493
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 455
Lazarević, T., Simović, A. R., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 429
Timms, K. M., Abkevich, V., Hughes, E., Neff, C. D., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 418
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Self-citationClarke, N. W., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., Redfern, C. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 405
Bono, J. S. D., Ramanathan, R. K., Mina, L. A., Chugh, R. K., Glaspy, J. A., Rafii, S., Kaye, S. B., Sachdev, J. C., Heymach, J. V., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 390
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 384
DNA double-strand break repair pathway choice and cancer
Aparicio, T., Baer, R., & Gautier, J. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.03.014 · Cited by 347
PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
Pilie, P. G., Gay, C. M., Byers, L. A., O’Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 343
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Karzai, F. H., VanderWeele, D. J., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., Couvillon, A., Nichols, E. H., Bilušić, M., Beshiri, M. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0463-2 · Cited by 311
Sun, C., Yin, J., Fang, Y., Chen, J., Jeong, K. J., Chen, X., Vellano, C. P., Ju, Z., Zhao, W., Zhang, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.019 · Cited by 306
Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S. P., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam7479 · Cited by 297
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Asim, M., Tarish, F., Zecchini, H. I., Sanjiv, K., Gelali, E., Massie, C. E., Baridi, A., Warren, A. Y., Zhao, W., Ogris, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00393-y · Cited by 291
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38534-6 · Cited by 253
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Faraoni, I., & Graziani, G. (2018) · Cancers · doi:10.3390/cancers10120487 · Cited by 239
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Sun, C., Fang, Y., Yin, J., Chen, J., Ju, Z., Zhang, D., Chen, X., Vellano, C. P., Jeong, K. J., Ng, P. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5148 · Cited by 237
Genomic evolution of cancer models: perils and opportunities
Ben‐David, U., Beroukhim, R., & Golub, T. R. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 234
Cancer immunotherapy beyond immune checkpoint inhibitors
Marin-Acevedo, J. A., Soyano, A. E., Dholaria, B., Knutson, K. L., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0552-6 · Cited by 222
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
Mengwasser, K. E., Adeyemi, R. O., Leng, Y., Choi, M. Y., Clairmont, C. S., D’Andrea, A. D., & Elledge, S. J. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.008 · Cited by 203
Yang, J., & Hu, L. (2018) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 201
Balmus, G., Pilger, D., Coates, J., Demir, M., Sczaniecka-Clift, M., Barros, A. C., Woods, M., Fu, B., Yang, F., Chen, E. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07729-2 · Cited by 195
Thomas, A., Vilimas, R. J., Trindade, C. J., Erwin-Cohen, R. A., Roper, N., Xi, L., Krishnasamy, V. P., Levy, E. B., Mammen, A., Nichols, S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.026 · Cited by 186
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
Self-citationCheng, C.-M., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali‐Osman, F., Szabó, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P. L., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171
Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 159
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Keung, M., Wu, Y., & Vadgama, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040435 · Cited by 158
Mukhopadhyay, A., Plummer, E. R., Elattar, A., Soohoo, S., Uzir, B. F., Quinn, J. E., McCluggage, W. G., Maxwell, P., Aneke, H., Curtin, N. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0324 · Cited by 151
Checkpoint inhibitors in hematological malignancies
Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 139
DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Jalal, S. I., Earley, J. N., & Turchi, J. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0761 · Cited by 138
Friedlander, M. L., Gebski, V., Gibbs, E., Davies, L. C., Bloomfield, R., Hilpert, F., Wenzel, L. B., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30343-7 · Cited by 135
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 132
Self-citationThe Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 130
Gupta, S. K., Kizilbash, S. H., Carlson, B. L., Mladek, A. C., Boakye‐Agyeman, F., Bakken, K. K., Pokorny, J. L., Schroeder, M. A., Decker, P. A., Cen, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv369 · Cited by 128
Smith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R. G., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2572 · Cited by 122
Lesueur, P., Lequesne, J., Grellard, J., Dugué, A. E., Coquan, E., Brachet, P.-E., Geffrelot, J., Kao, W., Emery, É., Berro, D. H., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5413-y · Cited by 117
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 115
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhang, Z., Ma, P., Jing, Y., Yan, Y., Cai, M., Zhang, M., Zhang, S., Peng, H., Ji, Z., Di, W. J., et al. (2015) · Theranostics · doi:10.7150/thno.13178 · Cited by 103
Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs393 · Cited by 99
Hussain, M., Carducci, M. A., Slovin, S. F., Cetnar, J. P., Qian, J. X., McKeegan, E. M., Refici-Buhr, M., Chyla, B., Shepherd, S. P., Giranda, V. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0099-0 · Cited by 97
Rodler, E. T., Kurland, B. F., Griffin, M., Gralow, J. R., Porter, P. L., Yeh, R. F., Gadi, V. K., Guenthoer, J., Beumer, J. H., Korde, L. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2137 · Cited by 96
The cell cycle checkpoint inhibitors in the treatment of leukemias
di Rorà, A. G. L., Iacobucci, I., & Martinelli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0443-x · Cited by 95
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
Gröschel, S., Hübschmann, D., Raimondi, F., Horak, P., Warsow, G., Fröhlich, M., Klink, B., Gieldon, L., Hutter, B., Kleinheinz, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09633-9 · Cited by 92
Terada, M., Fujiki, H., Marks, P. A., & Sügimura, T. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.12.6411 · Cited by 89
Patterns of Genomic Instability in Breast Cancer
Kalimutho, M., Nones, K., Srihari, S., Duijf, P. H. G., Waddell, N., & Khanna, K. K. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.005 · Cited by 87
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Portarena, I., Zupi, G., Bonmassar, E., & Graziani, G. (2002) · Blood · doi:10.1182/blood.v99.6.2241 · Cited by 83
Aberrations in DNA repair pathways in cancer and therapeutic significances
Motegi, A., Masutani, M., Yoshioka, K., & Bessho, T. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.005 · Cited by 76
A change of view: homologous recombination at single-molecule resolution
Kaniecki, K., Tullio, L. D., & Greene, E. C. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.92 · Cited by 75
Gray, H. J., Bell‐McGuinn, K. M., Fleming, G. F., Cristea, M. C., Xiong, H., Sullivan, D. M., Luo, Y., McKee, M. D., Munasinghe, W. P., & Martin, L. P. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.029 · Cited by 73
The evolving landscape of predictive biomarkers of response to PARP inhibitors
Thomas, A., Murai, J., & Pommier, Y. G. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120388 · Cited by 72
Emerging therapies for breast cancer
Hu, X., Huang, W., & Fan, M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0466-3 · Cited by 71
Gojo, I., Beumer, J. H., Pratz, K. W., McDevitt, M. A., Baer, M. R., Blackford, A. L., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0984 · Cited by 65
Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System.
Schreck, K. C., & Grossman, S. A. (2018) · PubMed · Cited by 65
Pérez, J. M., Soto, M., Quevedo, C., Alonso‐Moreno, C., Cepeda, V., Fuertes, M. A., & Nguewa, P. (2005) · Medicinal Chemistry · doi:10.2174/157340606775197697 · Cited by 62
Chen, X., Huan, X., Liu, Q., Wang, Y., He, Q., Tan, C., Chen, Y., Ding, J., Xu, Y., Miao, Z., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.018 · Cited by 54
Targeting DNA repair in breast cancer: A clinical and translational update
Amir, E., Šeruga, B., Serrano, R., & Ocaña, A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.006 · Cited by 52
Metzger, M. J., Stoddard, B. L., & Monnat, R. J. (2013) · DNA repair · doi:10.1016/j.dnarep.2013.04.004 · Cited by 51
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
Lu, Y., Liu, Y., Pang, Y. K., Pacák, K., & Yang, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.006 · Cited by 51
Liu, F. W., & Tewari, K. S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0378-9 · Cited by 46
Base Excision Repair Gene Polymorphisms and Wilms Tumor Susceptibility
Zhu, J., Jia, W., Wu, C., Fu, W., Xia, H., Liu, G., & He, J. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.06.018 · Cited by 46
Gabrielson, A. T., Tesfaye, A. A., Marshall, J. L., Pishvaian, M. J., Smaglo, B. G., Jha, R. C., Dorsch‐Vogel, K., Wang, H., & He, A. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2852-2 · Cited by 42
Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: Talazoparib
McCann, K. E. (2019) · Future Oncology · doi:10.2217/fon-2018-0751 · Cited by 35
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
Shao, N., Shi, Y., Yu, L., Ye, R., Shan, Z., Zhang, Z., Zhang, Y., & Lin, Y. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30721 · Cited by 18
The Role of Niraparib for the Treatment of Ovarian Cancer
Ethier, J.-L., Lheureux, S., & Oza, A. M. (2018) · Future Oncology · doi:10.2217/fon-2018-0101 · Cited by 15
Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
Pearre, D. C., & Tewari, K. S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149248 · Cited by 13
Association of a novel point mutation in MSH2 gene with familial multiple primary cancers
Hu, H., Li, H., Jiao, F., Han, T., Zhuo, M., Cui, J., Li, Y., & Wang, L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0523-y · Cited by 7
PARP Inhibition in Ovarian Cancer: State of the Science
Gunderson, C. C., & Moore, K. N. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.009 · Cited by 4
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Self-citationCD44 as a tumor biomarker and therapeutic target
Xu, H., Niu, M., Yuan, X., Wu, K., & Liu, A. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00192-0 · Cited by 390
Self-citationRecent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 351
Self-citationThe therapeutic potential of targeting regulated non-apoptotic cell death
Hadian, K., & Stockwell, B. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00749-8 · Cited by 349
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 343
Metadata
- Authors
- Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S.
- Affiliations
- Tongji Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Wu, Kongming
- Luo, Suxia
- Venue
- Experimental Hematology & Oncology
- Published
- 2019-11-11
- Volume
- 8
- Issue
- 1
- Pages
- 29-29
- ISSN
- 2162-3619 (ISSN-L)
- PMC
- PMC6849303
- OpenAlex
- W2987653633
- Cited by
- 117
- References
- 104
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 7 · 2023: 18 · 2022: 19 · 2021: 33 · 2020: 22
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Experimental Hematology and Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81874120, 81572608, 81672984)
- Wuhan Municipal Science and Technology Bureau (2017060201010170)
- Natural Science Foundation of Henan Province (162300410266)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- PARP inhibitors, DNA repair deficiency, synthetic lethality, BRCA mutations, homologous recombination deficiency, single-strand break repair, genomic instability, PARP inhibitor resistance, combination therapy, immune checkpoint inhibitors, combination chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
